Ostrowski Rochella A, Bussey Melissa R, Shayesteh Yasmin, Jay Walter M
Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Loyola University Chicago, Stritch School of Medicine Maywood, Illinois USA and.
Department of Ophthalmology, Loyola University Chicago, Stritch School of Medicine Maywood, Illinois USA.
Neuroophthalmology. 2015 Jun 17;39(3):109-115. doi: 10.3109/01658107.2015.1039140. eCollection 2015 Jun.
Graves disease is an autoimmune thyroid disease classically characterised by a clinical triad consisting of hyperthyroidism, diffuse goitre, and thyroid eye disease. Thyroid eye disease is an immunologically mediated condition in which humoral immunity is thought to play a central role. Thyroid eye disease is traditionally treated with high-dose glucocorticosteroids and surgical orbital decompression. However, responses are inadequate and alternative treatment options are needed. Rituximab, an anti-CD20 monoclonal antibody, shows promise as a novel therapeutic option for thyroid eye disease. There are 43 cases of thyroid eye disease treated with rituximab in the medical literature, and larger studies are warranted to determine the long-term effectiveness of rituximab. Rituximab may represent an attractive new treatment option for thyroid eye disease, especially in the case of disease that is refractory to current treatment strategies.
格雷夫斯病是一种自身免疫性甲状腺疾病，其典型特征是由甲状腺功能亢进、弥漫性甲状腺肿和甲状腺眼病组成的临床三联征。甲状腺眼病是一种免疫介导的疾病，其中体液免疫被认为起核心作用。传统上，甲状腺眼病采用大剂量糖皮质激素和眼眶减压手术治疗。然而，治疗效果并不理想，需要其他治疗选择。利妥昔单抗是一种抗CD20单克隆抗体，有望成为甲状腺眼病的一种新型治疗选择。医学文献中有43例甲状腺眼病患者接受了利妥昔单抗治疗，需要进行更大规模的研究来确定利妥昔单抗的长期疗效。利妥昔单抗可能是甲状腺眼病一种有吸引力的新治疗选择，尤其是对于目前治疗策略难治的疾病。
